Late-breaking clinical results demonstrate the DESyne® BDS Plus system with site-specific antithrombotic therapeutic (TRx) significantly reduces the risk of target lesion failure (TLF) versus conventional DES. tinyurl.com/4a9xck2v #EuroPCR

Coming off a great #EuroPCR 2024! We were thrilled to share data on our transformational technologies and connect with those leading the way in #cardiovascular medicine! Flavio Ribichini, MIЯVΛƬ #IC, Michal Hawranek, Valeria Paradies, Dr Roxana Mehran Dr. AlexandreAbizaid

We’re thrilled that #EuroPCR recognized the two-year #BIOADAPTOR RCT as one of its top 3 trials and DESyne® BDS Plus as a top innovation in the 2024 Highlights. 🎖🏆Learn more about the data: elixirmedical.com/clinical-evide… #Medtech #Innovation #CardioTwitter

ICYMI: At #EuroPCR, we shared late-breaking 2-year data showing #DynamX® Coronary Bioadaptor’s significant clinical advantages vs. DES. Learn more about the results: elixirmedical.com/clinical-evide… CE marked. Not for sale in the U.S. #Bioadaptor #Medtech #Innovation #CardioTwitter

ICYMI: New PINNACLE I study data demonstrate the effectiveness of LithiX™ IVL’s unique MOA across a broad range of moderate to severe calcified lesion morphologies with more than 90% of lesions demonstrating fractures. Learn more: elixirmedical.com/europcr-2024-p… #EuroPCR

ICYMI: We presented late-breaking clinical results at #EuroPCR 2024 demonstrating a 77% lower target lesion failure (TLF) rate with the DESyne® BDS Plus system with TRx compared to conventional DES. Learn more about the results: elixirmedical.com/europcr-2024-e… #CardioTwitter

“The study suggests “an edge” with Bioadaptor in terms of TLF over the drug-eluting stent.” - Robert Byrne. Read TCTMD’s article on the #BIOADAPTOR RCT: tctmd.com/news/solid-2-y… Michael O'Riordan MIЯVΛƬ #IC #cardiotwitter CE marked. Not approved in the U.S. PMN 1887 REV A

#BreakingNews: #DynamX Sirolimus-Eluting Coronary #Bioadaptor System has been granted FDA Breakthrough Device Designation for the treatment of symptomatic ischemic heart disease. elixirmedical.com/elixir-medical… #cardiotwitter CE marked. Not for sale in the U.S. PMN 1891 REV A

Congratulations kadiko for taking home gold and silver in the 2024 @TellyAwards for work on the #DynamX bioadaptor animation. Check out the award-winning animation here: elixirmedical.com/videos/?playli… #cardiotwitter CE marked. Not for sale in the U.S. PMN 1889 REV A

At #EuroPCR 2024, global experts discussed complex procedures performed with #DynamX® Coronary Bioadaptor System & how restoring vessel viability leads to clinical benefits. bit.ly/4d1WE8N CE marked. Not for sale in the U.S. PMN 1938 REV A

ICYMI: Watch Antonio Colombo, Stefan Verheye, M.D., & Davide Capodanno share perspectives on #BIOADAPTOR RCT 2-year outcomes at #EuroPCR 2024 here: bit.ly/3XVO7ji CE marked. Not for sale in the U.S. #CardioTwitter PMN 1939 REV A

Congratulations Prof. Letilović, Prof. Starcevic, Dr. Richter, and Chief Nurse Mrs. Posilovic and her team at Clinical Hospital Merkur Zagreb for advancing patient care by completing their first bioadaptive angioplasty cases with #DynamX. Learn more: elixirmedical.com/technologies/

📣 Have you heard? #DynamX is available in leading innovation centers around the world! Michal Hawranek shares why he offers the therapy to his patients. Watch the full video here: bit.ly/4dtS3gh CE marked. Not for sale in the U.S. #cardiotwitter PMN 1943 Rev A

At #ESC2024, we’ll unveil late-breaking, 12-month primary outcomes from the 2,400-patient INFINITY-SWEDEHEART RCT evaluating #DynamX compared to contemporary DES. Read more: bwnews.pr/3X19EWL David Erlinge Stefan James CE marked. Not for sale in the U.S. PMN 1894 REV A

You won’t want to miss this! Watch Dr. Bambang Budiono as he highlights the #DynamX bioadaptor’s unique mechanism of action & how it’s designed to help restore vessel function: bit.ly/46TO4XT CE marked. Not for sale in the U.S. #cardiotwitter PMN 1947 Rev A

💡 Watch the full video of Dr. Teguh Santoso as he discusses his experience with the #DynamX bioadaptor! bit.ly/4dxgVmP CE marked. Not for sale in the U.S. #cardiotwitter PMN 1945 Rev A

Watch MIЯVΛƬ #IC as she offers her perspective on the BIOADAPTOR RCT two-year data and the impact the results could have on her practice and the future of PCI. #cardiotwitter #Bioadaptor CE marked. Not for sale in the U.S. PMN 1993 REV A

Congratulations to Dr. Julia Mascherbauer, Dr. Paul Vock and the team at St. Pölten University on your first #DynamX implant in the BIO-RESTORE post-market registry. #cardiotwitter CE marked. Not for sale in the U.S. PMN 1991 Rev A

🚨INFINITY-SWEDEHEART: #DynamX® Bioadaptor meets primary endpoint and significantly reduces adverse events vs. DES after six months! Full data: businesswire.com/news/home/2024… CE marked. Not for sale in the U.S. #cardiotwitter #ESC2024 PMN 2001 REV A

📣 Don’t miss out on the future of PCI outcomes webinar coming up on September 18 hosted by incathlab. Learn more: incathlab.com/en/lives/19-ca… CE marked. Not for sale in the U.S. #cardiotwitter #DynamX® PMN 2006 Rev A